Moderna and Merck's mRNA Cancer Vaccine Cuts Death and Recurrence Risk by 42%

Moderna and Merck have released top-line results from a clinical trial of their mRNA cancer vaccine, and the headline number is a 42% reduction in the risk of death or cancer recurrence among patients in the study.

The companies had already said the trial met its main goal, so this release supplies the figures behind that earlier claim. A top-line announcement gives the headline result without the full dataset. Outside researchers have not yet been able to examine the patient-level data, the safety findings, or the statistical detail behind the 42% figure.

The vaccine is one of the most closely watched uses of mRNA technology beyond COVID-19. The platform Moderna used for its pandemic shots is being applied here to help the immune system recognize cancer cells, and a positive late-stage result would be among the strongest signs yet that the approach can work against tumors.

Full results will still need to be presented at a medical meeting and peer reviewed before the size of the benefit can be properly judged, including how long it lasts and how it performed across different patient groups.